Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.
Phase of Trial: Phase II
Latest Information Update: 01 Feb 2012
At a glance
- Drugs Methylprednisolone; Methylprednisolone; Octreotide
- Indications Cancer metastases; Solid tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Feb 2012 Results published in the Bulletin du Cancer.
- 13 Apr 2010 Planned end date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
- 30 Mar 2010 Actual patient number (64) added as reported by ClinicalTrials.gov.